WallStSmart

enVVeno Medical Corp (NVNO)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

SYK leads profitability with a 13.2% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 55/100 (C-).

NVNO

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -2.51

SYK

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 6.5Value: 3.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NVNO.

SYKSignificantly Overvalued (-47.5%)

Margin of Safety

-47.5%

Fair Value

$223.53

Current Price

$329.78

$106.25 premium

UndervaluedFair: $223.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVNO2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$125.40B9/10

Large-cap with strong market position

Areas to Watch

NVNO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

SYK4 concerns · Avg: 3.8/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
37.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVNO

The strongest argument for NVNO centers on Price/Book, Debt/Equity.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap.

Bear Case : NVNO

The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

NVNO carries more volatility with a beta of 1.09 — expect wider price swings.

SYK is growing revenue faster at 2.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (55/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

enVVeno Medical Corp

HEALTHCARE · MEDICAL DEVICES · USA

enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?